Bitter taste receptors as a target for bronchodilation

Area of Science:

• Pulmonary pharmacology
• Respiratory system research
• Taste receptor signaling

Background:

• Current asthma therapies like beta-agonists and glucocorticoids often fail to provide adequate control for many patients.
• Recent discovery of bitter taste receptors (TAS2R) in the human airway presents a new therapeutic avenue.

Discussion:

• This study investigated TAS2R agonists for bronchodilation effects in human airway smooth muscle cells, isolated bronchial smooth muscle, and a mouse asthma model.
• Results confirm TAS2R as a viable target for bronchodilation, demonstrating its potential in asthma management.

Key Insights:

• Bitter taste receptor (TAS2R) activation leads to bronchodilation.
• TAS2R agonists show promise as a novel therapeutic strategy for asthma.
• Diverse bitter compounds may have multiple mechanisms, necessitating selective TAS2R agonist development.

Outlook:

• Further research is needed to develop selective TAS2R agonists for targeted asthma therapy.
• Clinical potential of TAS2R in asthma requires investigation into specific agonist efficacy and safety.
• Selective TAS2R agonists could offer a new class of bronchodilators for difficult-to-control asthma.